Related Experiment Videos
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative
Anne G Semb1, Ingar Holme, Tore K Kvien
1Department of Rheumatology, Diakonhjemmet Hospital, NO-0319 Oslo, Norway. a-semb@diakonsyk.no
Rheumatoid arthritis (RA) patients with coronary heart disease (CHD) experienced similar cardiovascular event rates and lipid reductions with statin therapy compared to those without RA. These findings highlight effective secondary prevention in RA patients, despite lower baseline cholesterol levels.
Area of Science:
- Cardiology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) significantly increases the risk of coronary heart disease (CHD).
- Secondary prevention strategies, including statin use, are crucial for RA patients with established CHD.
- Limited data exists on statin efficacy in RA patients with CHD.
Purpose of the Study:
- To evaluate the effect of statin treatment on lipid levels in RA patients with CHD.
- To assess the incidence of cardiovascular disease (CVD) events in RA patients undergoing statin therapy.
- To compare outcomes in RA patients versus the general population within the IDEAL study.
Main Methods:
- Exploratory analysis of the IDEAL study, including 87 RA patients with prior myocardial infarction (MI).
- Patients were randomized to atorvastatin 80 mg or simvastatin 20-40 mg daily.
- Lipid levels and composite secondary endpoint (any CVD event) were analyzed over 4.8 years.
Main Results:
- RA patients exhibited lower baseline total and LDL cholesterol levels compared to non-RA patients.
- Both atorvastatin and simvastatin demonstrated comparable lipid-lowering effects in RA patients.
- Cardiovascular event rates were similar between RA patients (26.4%) and the general IDEAL population (28.7%).
Conclusions:
- Statin therapy provides comparable lipid-lowering efficacy in RA patients with previous MI as in the general population.
- RA patients with previous MI experienced similar rates of cardiovascular events compared to their non-RA counterparts.
- Lower baseline cholesterol in RA patients did not alter the effectiveness of statin treatment or CVD event rates.
Related Concept Videos
Atherosclerosis III: Management
Rheumatic Heart Disease III: Medical Management
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Rheumatic Heart Disease IV: Nursing Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction